Total Payments
$17,521
2024 Payments
$939.85
Companies
60
Transactions
440
Medicare Patients
1,015
Medicare Billing
$335,933
Payment Breakdown by Category
Consulting$8,725 (49.8%)
Food & Beverage$7,423 (42.4%)
Travel$704.07 (4.0%)
Education$668.53 (3.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,725 | 2 | 49.8% |
| Food and Beverage | $7,423 | 428 | 42.4% |
| Travel and Lodging | $704.07 | 2 | 4.0% |
| Education | $668.53 | 8 | 3.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,716 | 24 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,260 | 5 | $0 (2023) |
| Merck Sharp & Dohme LLC | $577.27 | 38 | $0 (2024) |
| Gilead Sciences, Inc. | $551.55 | 28 | $0 (2023) |
| Janssen Biotech, Inc. | $525.85 | 25 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $486.20 | 30 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $460.75 | 36 | $0 (2019) |
| Astellas Pharma US Inc | $363.03 | 12 | $0 (2024) |
| EMD Serono, Inc. | $350.32 | 29 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $286.55 | 14 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $939.85 | 37 | SOBI, INC ($175.54) |
| 2023 | $1,408 | 66 | Janssen Biotech, Inc. ($174.42) |
| 2022 | $290.68 | 15 | Janssen Biotech, Inc. ($49.87) |
| 2021 | $29.53 | 2 | AbbVie Inc. ($29.53) |
| 2020 | $99.95 | 1 | SANOFI-AVENTIS U.S. LLC ($99.95) |
| 2019 | $10,191 | 68 | Novartis Pharmaceuticals Corporation ($8,457) |
| 2018 | $1,413 | 105 | Merck Sharp & Dohme Corporation ($128.73) |
| 2017 | $3,148 | 146 | Bayer HealthCare Pharmaceuticals Inc. ($1,224) |
All Payment Transactions
440 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.75 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/10/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $4.56 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/18/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: BioOncology | ||||||
| 11/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: Oncology | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Oncology | ||||||
| 10/01/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/24/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: BioOncology | ||||||
| 09/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $31.41 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Oncology | ||||||
| 08/29/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: Hematology | ||||||
| 08/27/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $91.40 | General |
| Category: Oncology | ||||||
| 08/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Oncology | ||||||
| 07/29/2024 | GENZYME CORPORATION | CABLIVI (Biological), ENJAYMO | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: Hematology | ||||||
| 07/22/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Oncology | ||||||
| 06/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: ONCOLOGY | ||||||
| 05/30/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 05/14/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 345 | 11,791 | $422,617 | $218,336 |
| 2022 | 8 | 267 | 4,331 | $121,538 | $81,929 |
| 2021 | 5 | 144 | 250 | $27,500 | $16,417 |
| 2020 | 7 | 259 | 425 | $39,444 | $19,252 |
Total Patients
1,015
Total Services
16,797
Medicare Billing
$335,933
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 94 | 10,980 | $373,320 | $200,891 | 53.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 80 | $12,160 | $7,559 | 62.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 56 | $9,632 | $2,656 | 27.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 104 | 251 | $10,570 | $2,519 | 23.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 24 | $2,407 | $1,654 | 68.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 32 | 161 | $1,615 | $1,305 | 80.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 31 | 153 | $2,754 | $1,164 | 42.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 15 | 86 | $10,159 | $587.28 | 5.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 49 | 3,900 | $92,160 | $67,115 | 72.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 66 | $10,633 | $6,676 | 62.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 22 | $4,837 | $3,108 | 64.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 19 | 39 | $6,708 | $2,138 | 31.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 56 | 99 | $3,492 | $1,056 | 30.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $1,332 | $862.38 | 64.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 33 | 87 | $1,566 | $664.07 | 42.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 45 | 105 | $810.00 | $309.96 | 38.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 48 | 113 | $13,164 | $7,950 | 60.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 52 | 78 | $6,544 | $3,665 | 56.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 17 | $4,352 | $2,826 | 64.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 17 | 23 | $2,300 | $1,372 | 59.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 12 | 19 | $1,140 | $604.20 | 53.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 80 | 146 | $15,662 | $6,103 | 39.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 36 | 79 | $10,044 | $4,984 | 49.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 63 | 101 | $5,184 | $3,892 | 75.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 12 | $3,072 | $2,059 | 67.0% |
About Dr. Anibal Drelichman, MD
Dr. Anibal Drelichman, MD is a Medical Oncology healthcare provider based in Southfield, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740222447.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anibal Drelichman, MD has received a total of $17,521 in payments from pharmaceutical and medical device companies, with $939.85 received in 2024. These payments were reported across 440 transactions from 60 companies. The most common payment nature is "Consulting Fee" ($8,725).
As a Medicare-enrolled provider, Drelichman has provided services to 1,015 Medicare beneficiaries, totaling 16,797 services with total Medicare billing of $335,933. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Southfield, MI
- Active Since 06/10/2006
- Last Updated 02/18/2011
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1740222447
Products in Payments
- ADAKVEO (Biological) $8,020
- Stivarga (Drug) $1,236
- KEYTRUDA (Biological) $403.68
- OPDIVO (Biological) $358.93
- Imbruvica (Drug) $286.55
- Bavencio (Biological) $264.81
- Lenvima (Drug) $257.57
- IMFINZI (Drug) $230.30
- FOTIVDA (Drug) $204.96
- DARZALEX (Biological) $197.33
- TRIUMEQ (Drug) $191.13
- SOMATULINE DEPOT (Drug) $137.62
- Rubraca (Drug) $124.99
- VONJO (Drug) $124.99
- TAGRISSO (Drug) $115.62
- Epclusa (Drug) $105.78
- JEVTANA (Drug) $99.95
- Descovy (Drug) $99.13
- PICO 7 Single Use Negative Pressure Wound Therapy (Device) $98.58
- Enhertu (Drug) $96.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.